Alan Hutson

PhD, MA

Research Interests:

Clinical trial design, computational methods and order statistics

About Alan Hutson

Biography:

Dr. Hutson is Chair of Biostatistics and Bioinformatics at Roswell Park Comprehensive Cancer Center and Associate Director of the Biostatistics Shared Resource. He received his B.A. (1988) and M.A. (1990) in Statistics from the State University of New York (SUNY) at Buffalo. He then worked for Otsuka America Pharmaceuticals for two years as a biostatistician. Dr. Hutson then received his M.A. (1993) and Ph.D. (1996) in Statistics from the University of Rochester. His Ph.D. advisor was Professor Govind Mudholkar, a world-renown researcher in Statistics and Biostatistics.
Dr. Hutson was hired as a biostatistician at the University of Florida in 1996 as a Research Assistant Professor and worked his way to Associate Professor. He had several roles at the University of Florida including Interim Director of the Division of Biostatistics and Director of the General Clinical Research Informatics Core.
Dr. Hutson moved to the State University of New York at Buffalo in 2002 as an Associate Professor and Chief of the Division of Biostatistics. He was the founding chair of the new Department of Biostatistics in 2003 and became a full professor in 2007.
Dr. Hutson’s accomplishments as Chair included the implementation of several new undergraduate and graduate degree programs and a substantial growth in the size and quality of the department faculty and students. In 2005 Dr. Hutson became Chair of Biostatistics (now Biostatistics and Bioinformatics) at Roswell Park Comprehensive Cancer Center (Roswell Park), was appointed to Professor of Oncology and was the Director of the CCSG Biostatistics Shared Resource. Dr. Hutson helped implement the new Bioinformatics Shared Resource at Roswell Park and the Biomedical Research Informatics Shared Resource. He is Associate Editor of Communications in Statistics and is on the editorial board for Cancers. He is also a New York State NYSTAR Distinguished Professor and Fellow of the American Statistical Association.
Dr. Hutson’s has membership on several data safety and monitoring boards and has served on several high-level scientific review panels. He has over 300 peer reviewed publications and two monographs. Dr. Hutson’s methodological work focuses on nonparametric methods for biostatistical applications as it pertains to statistical functionals. He has several years of experience in the design and analysis of clinical trials. Currently Dr. Hutson is serving on SITC’s Data Sharing and Big Data Taskforce. He is also the contact MPI for the Cancer Moonshot U24 grant Immuno-Oncology Translational Network (IOTN): Data Management and Resource Sharing Center at RPCI and the Cancer Moonshot Acquired Resistance to Therapy Network (ARTNet)Coordinating Center. He is currently Chair of the IOTN Steering Committee and co-Chair of the ARTNet Steering Committee.

Positions

Roswell Park Comprehensive Cancer Center
  • Chair of Biostatistics and Bioinformatics
  • Professor of Oncology
  • Department of Biostatistics and Bioinformatics

State University of New York at Buffalo

  • Research Professor

Background

Education and Training:

  • 1996 - PhD - Statistics ,University of Rochester, Rochester, NY
  • 1993 - MA - Statistics, University of Rochester, Rochester, NY
  • 1990 - MA - Statistics, State University of New York at Buffalo, Buffalo, NY
  • 1988 - BA - Statistics, State University of New York at Buffalo, Buffalo, NY

Professional Memberships:

  • American Statistical Association (Fellow)
  • Society for Controlled Clinical Trials, Member of the Society for Immunotherapy of Cancer (SITC)
  • American Association for Cancer Research (AACR)

Honors & Awards:

  • 2013 - Inducted into Delta Omega Public Health Honor Society, Gamma Lambda Chapter (inaugural selection)
  • 2011 - Elected Fellow of the American Statistical Association
  • 2010 - UB School of Public Health and Health Professions Outstanding Senior Researcher
  • 2004 - UB School of Public Health and Health Professions Dean’s Award
  • 2001 - NYSTAR Distinguished Professor with Recognized Excellence in Bioinformatics

Publications

Full Publications list on PubMed
  • Ambrosone, C.B., Zirpoli, G,R., Hutson, A.D., McCann, W.E., McCann, S.E., Barlow, W.E., Kelly, K.M., Cannioto, R., Sucheston-Campbell, L.E., Hershman, D.L., Unger, J.M., Moore, H.C.F., Stewart, J.A., Isaacs, C., Hobday, T.J., Salim, M., Hortobagyi, G.N., Gralow, J.R., Budd, G.T. & Albain, K.S. (2020) Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin Oncol, 38(8): 804-814
  • Cannioto, R.A., Hutson, A., Dighe, S., McCann, W., McCann, S.E., Zirpoli, G.R., Barlow, W., Kelly, K.M., DeNysschen, C.A., Hershman, D.L., Unger, J.M., Moore, H.C.F., Stewart, J.A., Isaacs, C., Hobday, T.J., Salim, M., Hortobagyi, G.N., Gralow, J.R., Albain, K.S., Budd, G.T. & Ambrosone, C.B. (2020) Physical activity before, during and after chemotherapy for high-risk breast cancer: relationships with survival. J Natl Cancer Inst, doi: 10.1093/jnci/djaa046
  • Carlson, J.W., Kauderer, J., Hutson, A., Carter, J., Armer, J., Lockwood, S., Nolte, S., Stewart, B.R., Wenzel, L., Walker, J., Fleury, A., Bonebrake, A., Soper, J., Mathews, C., Zivanovic, O., Richards, W.E., Tan, A., Alberts, D.S. & Barakat, R.R. (2020) GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients. Gynecol Oncol, 156(2): 467-474
  • Shaurova, T., Dy, G.K., Battaglia, S., Hutson, A., Zhang, L., Zhang, Y., Lovly, C.M., Seshadri, M., Goodrich, D.W., Johnson, C.S. & Hershberger, P.A. (2020) Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance. Cancers (Basel), 12(3): 675
  • Chen, G.L., Hahn, T., Wilding, G.E., Groman, A., Hutson, A., Zhang, Y., Khan, U., Liu, H., Ross, M., Bambach, B., Higman, M., Neppalli, V., Sait, S., Block, A.W., Wallace, P.K., Singh, A.K. &  McCarthy, P.L. (2019) Reduced intensity conditioning with fludarabine, melphalan, and total body irradiation for allogeneic hematopoietic cell transplantation: the effect of increasing melphalan dose on underlying disease and toxicity. Biology of Blood and Marrow Transplantation, 25: 689-698
  • Kalathil, S., Hutson, A., Barbi, J., Iyer, R. & Thanavala, Y. (2019) Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of Hepatocellular Carcinoma (HCC) patients on sorafenib therapy. JCI Insights, 4: e130116
  • Hutson, A.D. (2019) A robust Pearson correlation test for a general point null using a surrogate bootstrap distribution. PLOS One, 14(5): e0216287
  • Hutson, A.D. & Vexler, A. (2018) A Cautionary Note on Beta Families of Distributions and the Aliases Within. The American Statistician, 72: 121-129
  • Wentink, M.Q., Verheul, H.M.W., Pal, S.K., George, S., Voortman, J., Danchaivijitr, P., Adelaiye, R., Poslinski, D., Groman, A., Hutson, A. & Pili, R. (2018)  Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma. Clinical Genitourinary Cancer, 16: e1-e9
  • Dong, T., Attwood, K., Hutson, A., Liu, S. & Tian, L. (2017) A new diagnostic accuracy measure and cut-point selection criterion. Statistical Methods in Medical Research, 26: 2832-2852
  • Pili, R., Quinn, D.I., Hammers. H., Monk, J.P., George, S., Dorff, T., Olencki, T., Shen, L., Orillion, A.R., Lamonica, D., Fragomeni, R.A.S., Szabo, Z., Hutson, A.D., Groman, A., Perkins, S.M., Piekarz, R.L. & Carducci, M.A. (2017) Immunomodulation by entinostat in renal cell carcinoma patients receiving high dose interleukin 2: a multicenter, single-arm, phase 1/2 trial (NCI-CTEP#7870). Clinical Cancer Research, 23: 7199-720
  • Fenstermaker, R.A., Ciesielski, M.J., Qiu, J., Yang, N., Frank, C.L., Lee, K.P., Mechtler, L.R., Belal, A., Ahluwalia, M.S. & Hutson, A.D.(2016) Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunology Immunotherapy, 65(11): 1339-1352
  • Hutson, A.D. (2016) Nonparametric rank based estimation of bivariate densities given censored data conditional on marginal probabilities. Journal of Statistical Distributions and Applications, 3:9. doi.org/10.1186/s40488-016-0047-y
  • Shan, G., Wilding, G.E., Hutson, A.D. & Gerstenberger, S. (2016) Optimal adaptive two-stage designs for early phase II clinical trials. Statistics in Medicine, 35: 1257-1266
  • Chandrasekhar, R., Shi, Y., Hutson, A.D. & Wilding, G.E. (2015) Likelihood-based inferences about the mean area under a longitudinal curve in the presence of observations subject to limits of detection. Journal of Biopharmaceutical Statistics, 14: 252-261
  • Hutson, A.D., Wilding, G.E., Mashtare, T.L. & Vexler, A. (2015) Measures of Biomarker Dependence Using a Copula Based Multivariate Epsilon-Skew-Normal Family of Distributions. Journal of Applied Statistics, 42: 2734-2753
  • Wei, L., Wang, D. & Hutson, A.D. (2015) An Investigation of Quantile Function Estimators Relative to Quantile Confidence Interval Coverage. Communications in Statistics – Theory and Methods, 44: 2107-2135
  • Fallavollita, J.A., Heavey, B.M., Luisi, A.J. Jr., Michalek, S.M., Baldwa, S., Mashtare, T.L., Jr., Hutson, A.D., Dekemp, R.A., Haka, M.S., Sajjad, M., Cimato, T.R., Curtis, A.B, Cain, M.E. & Canty, J.M., Jr. (2014). Regional Myocardial Sympathetic Denervation Predicts the Risk of Sudden Cardiac Arrest in Ischemic Cardiomyopathy. Journal of the American College of Cardiology, 63: 141-149
  • Shan, G., Ma, C.X., Hutson A.D. & Wilding, G.E. (2013) Randomized Two-Stage Phase II Clinical Trial Designs Based on Barnard’s Exact Test. Journal of Biopharmaceutical Statistics, 23: 1081-1090
  • Wang, D., Miecznikowski, J.C. & Hutson, A.D. (2012) Direct density estimation of L-estimates via characteristic functions with applications. Journal of Statistical Planning and Inference, 142: 5567-578
  • Wilding, G.E., Shan, G. & Hutson, A.D. (2012) Exact two-stage designs for phase II activity trials with rank-based endpoints. Contemporary Clinical Trials, 33: 332-341